Saito Y, Uzuka Y, Takahashi H, Komatsu M, Ito T
Tohoku J Exp Med. 1986 Jan;148(1):65-72. doi: 10.1620/tjem.148.65.
Twenty-three patients with chronic myelogenous leukemia (CML) in terminal transformation were treated with regimen incorporating vindesine and prednisolone with or without cytosine arabinoside. Twenty-one patients in blastic crisis (BC) were classified into subgroups on the blast cell morphology. Of these 21 patients, 5 (23.8%) had lymphoid morphology, 12 (57.2%) had myeloid morphology, and 4 (19.0%) had monocytoid morphology. All of five patients with lymphoid morphology and ten of twelve patients with myeloid morphology achieved complete remission (83.3%), while none of four patients with monocytoid morphology achieved complete remission. Two patients in accelerated phase also attained complete remission. Our results indicate that the regimens incorporating vindesine and prednisolone with or without cytosine arabinoside should be the treatment of choice in CML-BC both lymphoid and myeloid morphology and accelerated phase of CML as well.
23例处于终末期转化的慢性粒细胞白血病（CML）患者接受了包含长春地辛和泼尼松龙（加或不加阿糖胞苷）的治疗方案。21例处于急变期（BC）的患者根据原始细胞形态进行了分组。在这21例患者中，5例（23.8%）具有淋巴细胞形态，12例（57.2%）具有髓细胞形态，4例（19.0%）具有单核细胞样形态。所有5例具有淋巴细胞形态的患者和12例具有髓细胞形态的患者中的10例获得了完全缓解（83.3%），而4例具有单核细胞样形态的患者均未获得完全缓解。2例加速期患者也获得了完全缓解。我们的结果表明，包含长春地辛和泼尼松龙（加或不加阿糖胞苷）的治疗方案应是CML-BC中淋巴细胞和髓细胞形态以及CML加速期的首选治疗方法。
